ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

CEPH: Cephalon Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

CEPHALON INC (NASD)
CEPH	59.61	-0.10	(-0.17%)	Vol. 1,941,477	16:00 ET

Cephalon is an international biopharmaceutical company focused on thediscovery, development and marketing of products to treat sleep disorders,neurological disorders, cancer and pain. In addition to an active research and development program, they market products in the United States and various countries in Europe.

General Information

CEPHALON INC

41 Moores Road Frazer, PA 19355 Phone: 610 344-0200 Fax: 610 738-6590 Web: www.cephalon.com Email: investorrelations@cephalon.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/11/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	59.71
52 Week High	81.35
52 Week Low	52.55
Beta	0.48
20 Day Moving Average	2,197,462.50
Target Price Consensus	68.13

% Price Change
4 Week	10.55
12 Week	6.01
YTD	-22.63

% Price Change Relative to S&P 500
4 Week	9.36
12 Week	-0.06
YTD	-35.96

Share Information
Shares Outstanding (millions)	74.65
Market Capitalization (millions)	4,449.71
Short Ratio	3.98
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	1.58
Current Year EPS Consensus Estimate	5.94
Estimated Long-Term EPS Growth Rate	13.10
Next EPS Report Date	02/11/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.82
30 Days Ago	1.82
60 Days Ago	1.59
90 Days Ago	1.53

Fundamental Ratios

P/E
Current FY Estimate:	10.04
Trailing 12 Months:	10.24
PEG Ratio	0.77

EPS Growth
vs. Previous Year	37.29%
vs. Previous Quarter	12.50%

Sales Growth
vs. Previous Year	10.22%
vs. Previous Quarter:	0.29%

Price Ratios
Price/Book	1.83
Price/Cash Flow	7.57
Price / Sales	2.06

ROE
09/30/09	22.53
06/30/09	23.33
03/31/09	24.80

ROA
09/30/09	11.38
06/30/09	11.24
03/31/09	11.32

Current Ratio
09/30/09	1.89
06/30/09	1.89
03/31/09	1.13

Quick Ratio
09/30/09	1.70
06/30/09	1.69
03/31/09	1.03

Operating Margin
09/30/09	20.96
06/30/09	19.86
03/31/09	19.12

Net Margin
09/30/09	14.27
06/30/09	10.43
03/31/09	9.54

Pre-Tax Margin
09/30/09	14.27
06/30/09	10.43
03/31/09	9.54

Book Value
09/30/09	32.52
06/30/09	31.25
03/31/09	26.01

Inventory Turnover
09/30/09	2.19
06/30/09	2.86
03/31/09	3.58

Debt-to-Equity
09/30/09	0.15
06/30/09	0.15
03/31/09	0.00

Debt to Capital
09/30/09	12.84
06/30/09	13.26
03/31/09	0.30


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research